In summary, I would leave you with six points. First, with regard to the safety issue, I think that issue has largely been resolved. Second, I think we all concur that better dose-finding studies are needed. Third, we need a way to come up with a less cumbersome regimen for administering RU 486, particularly in conjunction with a prostaglandin analogue. Fourth, I think a great potential use for RU 486 and similar drugs is to augment second-trimester abortions. Fifth, another very exciting potential is use as a post-coital contraceptive. Sixth, and finally, we need much more work, such as we have heard this morning, with these other scores of compounds.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
B7. Comments on Session II ."
Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda . Washington, DC: The National Academies Press,
Please select a format: